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Summary
Background The post-2015 End TB Strategy sets global targets of reducing tuberculosis incidence by 50% and mortality 
by 75% by 2025. We aimed to assess resource requirements and cost-eﬀ ectiveness of strategies to achieve these 
targets in China, India, and South Africa.
Methods We examined intervention scenarios developed in consultation with country stakeholders, which scaled up 
existing interventions to high but feasible coverage by 2025. Nine independent modelling groups collaborated to 
estimate policy outcomes, and we estimated the cost of each scenario by synthesising service use estimates, empirical 
cost data, and expert opinion on implementation strategies. We estimated health eﬀ ects (ie, disability-adjusted life-
years averted) and resource implications for 2016–35, including patient-incurred costs. To assess resource 
requirements and cost-eﬀ ectiveness, we compared scenarios with a base case representing continued current practice.
Findings Incremental tuberculosis service costs diﬀ ered by scenario and country, and in some cases they more than 
doubled existing funding needs. In general, expansion of tuberculosis services substantially reduced patient-incurred 
costs and, in India and China, produced net cost savings for most interventions under a societal perspective. In all 
three countries, expansion of access to care produced substantial health gains. Compared with current practice and 
conventional cost-eﬀ ectiveness thresholds, most intervention approaches seemed highly cost-eﬀ ective.
Interpretation Expansion of tuberculosis services seems cost-eﬀ ective for high-burden countries and could generate 
substantial health and economic beneﬁ ts for patients, although substantial new funding would be required. Further 
work to determine the optimal intervention mix for each country is necessary. 
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Introduction 
The World Health Assembly’s post-2015 End TB 
Strategy formalises goals for aggressive action against 
tuber culosis, including reductions in global incidence 
by 50% and mortality by 75% by 2025.1 To meet these 
targets, major advances are needed in high-burden 
countries. The TB Modelling and Analysis Consortium 
conducted a multimodel evaluation to assess the goals’ 
feasibility,2 ﬁ nding that aggressive but feasible scale-up 
of existing approaches could achieve the reductions 
described by the global targets in South Africa but not in 
India or China.
If targets can be met, understanding whether doing so 
represents the best use of funding or is even aﬀ ordable is 
crucial. Conversely, if targets cannot be met, expansion 
of tuberculosis services is not without value. Although 
the End TB Strategy provides an important consensus to 
invigorate the ﬁ ght against tuberculosis and attract 
funding, Ministries of Health also need to consider local 
priorities and programmatic constraints. In this context, 
an understanding of the resources required for scale-up 
and a comparison of the performance of competing 
intervention approaches are crucial. 
In this analysis, we aimed to describe the costs and 
health outcomes of aggressive intervention against 
tuberculosis, and to assess cost-eﬀ ectiveness, ﬁ nancial 
implications, and patient economic burden of these 
interventions. Although previous studies3–5 have 
assessed the cost-eﬀ ectiveness of various interventions 
in high-burden settings, few have compared multiple 
interventions simultaneously and assessed aﬀ ordability. 
Quantiﬁ cation of the eﬀ ect of these interventions on 
patient-incurred costs is also important, in view of the 
high disease burden in low-resource settings6,7 and the 
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growing policy interest in catastrophic health-care 
spending,7,8 a concern addressed explicitly in the End TB 
Strategy.1
Methods 
Overview 
In collaboration with national tuberculosis programme 
representatives for each country, we deﬁ ned scenarios 
for scaling-up existing interventions to high yet feasible 
coverage by 2025. We projected long-term outcomes 
using multiple indepen dently developed models of 
tuberculosis epidemiology and health services, and 
estimated costs by synthesising model outputs with 
empirical cost data and expert opinion on imple-
mentation approaches. We estimated health eﬀ ects 
(disability-adjusted life-years [DALYs] averted) and 
resource implications for the 20 year period (2016–35), 
and calculated costs from multiple perspectives. For 
each country we compared intervention scenarios with a 
base case in which present intervention coverage is 
maintained.
Countries 
We undertook this study for China, India, and South 
Africa because of their substantial tuberculosis burden 
and their contrasting HIV and tuberculosis epidemiology 
and organisation of tuberculosis services. In China, 
tuberculosis incidence is 68 cases per 100 000 population 
and mortality is three per 100 000 population8 (equivalent 
to 3% of global tuberculosis mortality), and the country 
has achieved progressive reductions in tuberculosis 
burden  in the past three decades.9 In India, tuberculosis 
incidence is 167 per 100 000 population and mortality is 19 
per 100 000 population (accounting for 17% of global 
tuberculosis mortality), and a large private sector provides 
roughly half of all tuberculosis care.10 In South Africa, 
tuberculosis incidence is 834 per 100 000 population and 
mortality is 178 per 100 000 population (equivalent to 6% 
of global tuberculosis mortality), with both incidence and 
case fatality driven by the HIV epidemic.
Intervention scenarios
With input from national tuberculosis programme 
representatives for each country, we deﬁ ned scenarios 
describing scale-up of speciﬁ c interventions to high 
coverage by 2025 (table 1), making use of currently 
available intervention options and considering local 
policy preferences and capacity. Although intervention 
areas were deﬁ ned in advance, country experts deter-
mined whether additional scale-up of an intervention was 
appropriate for their country, and the anticipated scale 
and pace of coverage improvements. Scenario 
descriptions included the activities required to produce 
coverage changes: for example, in South Africa, 
Research in context
Evidence before this study
The World Health Assembly’s post-2015 End TB Strategy 
proposes aggressive action to reduce tuberculosis incidence and 
mortality worldwide. Major reductions in high-burden 
countries will be essential for achieving these targets. Before 
this study, little quantitative evidence existed on the feasibility 
of eﬀ orts to reach these targets in high-burden settings and on 
the cost of implementing aggressive service expansion. We 
reviewed published work (English-language articles identiﬁ ed 
on PubMed, supplemented by the authors’ familiarity of the 
relevant literature) on the cost-eﬀ ectiveness of tuberculosis 
interventions relevant to China, India, and South Africa. Most 
studies addressed only one intervention area, and few 
investigated issues of aﬀ ordability. Although the economic 
burden of tuberculosis on individuals and households is known 
to be high, few studies have estimated patient-incurred costs as 
part of cost-eﬀ ectiveness analysis. None of the studies reviewed 
were designed to address the issues raised by the global End TB 
Strategy targets. Collaborative analysis with multiple models to 
assess intervention cost-eﬀ ectiveness has previously been done 
for HIV policy changes but not for tuberculosis policy.
Added value of this study
In this study, we found that substantial improvements in the 
reach and quality of tuberculosis care might be cost-eﬀ ective 
according to conventional criteria, despite requiring 
substantially increased funding compared with current practice. 
By estimating patient-incurred costs at the same time as health 
service costs, we were able to understand the relative 
magnitude of these eﬀ ects—for some interventions, patient 
cost savings are larger than the additional costs borne by health 
services, leading to net cost savings under a societal 
perspective. By comparing multiple intervention approaches, 
our ﬁ ndings reveal the relative eﬃ  ciency of each approach in 
the generation of health beneﬁ ts. From these comparisons, 
eﬀ orts to improve access to care seemed the most beneﬁ cial 
and cost-eﬀ ective in each setting. Our ﬁ ndings also show 
substantial variation in results predicted by diﬀ erent models, 
pointing to important uncertainties in the evidence base for 
predicting long-term costs and health outcomes.
Implications of all the available evidence
Combined with evidence from previous cost-eﬀ ectiveness 
studies, the results of our analysis lend support to eﬀ orts to 
scale up tuberculosis services, motivated by the End TB targets. 
Our ﬁ ndings also reveal wide diﬀ erences in the eﬀ ect and 
eﬃ  ciency of diﬀ erent approaches, implying that countries will 
need to carefully consider the approaches taken to service 
expansion. The variation in results also shows a clear need for 
further empirical research to strengthen the evidence base used 
for tuberculosis policy modelling, and thereby improve the 
reliability of future analyses.
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improving access to tuberculosis diagnosis could be 
achieved through outreach to underserved areas and 
symptom screening for individuals attending primary 
care. Speciﬁ cation of activities helped to deﬁ ne the 
feasible extent of scale-up, and allowed the costs of each 
scenario to be estimated (see appendix p 3 for a description 
of  the disease course, treatment, and ﬁ nal outcomes). 
We assessed interventions separately and also 
considered a scenario representing the combination of 
all interventions for each country. A base case scenario 
represented continuation of current practice, with service 
coverage held at existing levels. Services not speciﬁ cally 
addressed in a scenario were held at current coverage 
levels, with two exceptions: for South Africa, we assumed 
that antiretroviral therapy (ART) coverage would increase 
to 77% by 2025; and for India, we assumed all retreatment 
tuberculosis cases would receive drug susceptibility 
testing by 2019. Both policies have high-level commitment 
in their respective countries. 
Modelling approach 
We projected policy outcomes using multiple 
independently developed Mycobacterium tuberculosis 
transmission models.3,11–19 Models had to represent the 
major mechanisms determining tuberculosis outcomes 
in each setting, be consistent with existing evidence on 
epidemiology and service provision, and simulate 
outcomes needed to estimate summary health and 
economic eﬀ ects. Of 11 models in the modelling exercise, 
nine fulﬁ lled these requirements and contributed inputs 
for the economic analysis (table 2; appendix pp 4–7), and 
additional details are provided by Houben and colleagues.2
Activities Timing and programme eﬀ ects* Mechanism of action for health eﬀ ects 
China
Expand access to care Local Centers for Disease Control and Prevention 
oﬃ  ces reimburse patients’ expenses and encourage 
tuberculosis care in designated hospitals
Population without access to tuberculosis care reduces 
from 5% to 3·75% by 2025. Population accessing high-
quality care increases from 80% to 95% by 2025
Reduced duration of infectiousness and mortality 
risks through improved case detection
Introduce Xpert 
MTB/RIF for diagnosis
Xpert replaces smear for routine diagnosis of new and 
retreatment cases
Xpert MTB-RIF coverage increases from 0% to 100% by 
2022
Minor improvement in diagnosis and  
improvement in  detection of drug-resistant cases
Improve treatment 
quality
Improve referral systems and sample transport; 
reimburse patient expenses; enhance mobile health, 
case management, and adherence support; improve 
management of side-eﬀ ects of MDR tuberculosis 
treatment
Initial default decreases from 3% to 1·5% by 2025 for 
drug-sensitive infections, and from 50% to 15% by 2025 
for drug-resistant infections. Treatment success increases 
from 82% to 90% by 2025 for drug-sensitive infections, 
and from 35% to 65% by 2025 for drug-resistant infections
Reduced initial default, and improved retention 
and cure rates for both drug-sensitive and 
drug-resistant cases
Combination All of the above All of the above All of the above
India
Expand access to care Pay subsidies for tuberculosis care in the private sector 
and increase microscopy access in the public sector 
Population without access to tuberculosis care decreases 
from 9·5% to 4·8% by 2022. Population accessing 
high-quality care increases from 50% to 90% by 2022
Reduced duration of infectiousness and mortality 
risks through improved case detection
Active case ﬁ nding in 
the general 
population†
Mobile screening units with symptom screen, x-ray, or 
Xpert algorithms
Achieve population coverage of 1·6% for annual screening 
from 2015 to 2020 
Reduced duration of infectiousness and mortality 
risks through improved case detection
Introduce Xpert 
MTB/RIF for diagnosis
Xpert replaces smear in routine diagnostic algorithm 
in the public sector
Xpert MTB-RIF coverage increases from 0% to 30% by 2019 Improvements in  tuberculosis diagnosis and 
detection of drug-resistant cases
Improve treatment 
quality
Improve private sector quality through provider 
training, supervision, regulation, and subsidies; 
provide patient retention incentives, nutritional 
support, and link to social welfare programmes
Initial default decreases from 10% to 5% by 2015 for 
drug-sensitive infections, and from 11% to 5% by 2020 for 
drug-resistant infections. Treatment success increases from 
75% to 85% by 2022 for drug-sensitive infections, and 
from 48% to 67% by 2022 for drug-resistant infections
Reduced initial default, improved retention and 
cure rates for both drug-sensitive and drug-
resistant cases
Combination All of the above All of the above All of the above
South Africa
Screening and IPT for 
individuals receiving 
ART
Screen current and new HIV-positive patients 
receiving ART and provide continuous IPT for all these 
patients without active tuberculosis
ART population on IPT increases from 5% to 80% by 2021 Treatment of active tuberculosis detected 
through screening and reduced progression to 
active tuberculosis for individuals on IPT
Expand access to care Provide outreach clinics to underserved areas and 
symptom screening in primary care
Population without access to tuberculosis care decreases 
from 5% to 0% by 2021
Reduced duration of infectiousness and mortality 
risks through improved case detection
Improve treatment 
quality
Provide mobile health and patient follow-up in 
community, adherence counselling, and improved 
staﬃ  ng for MDR tuberculosis
Initial default decreases from 17% to 5% by 2021 for 
drug-sensitive infections, and from 30% to 15% by 2021 
for drug-resistant infections. Treatment success increases 
from 76% to 85% by 2021 for drug-sensitive infections, 
and from 52% to 67% by 2025 for drug-resistant infections
Reduced initial default and improved retention 
and cure rates for both drug-sensitive and 
drug-resistant cases
Combination All of the above All of the above All of the above
MDR=multidrug-resistant. IPT=isoniazid preventive therapy. ART=antiretroviral therapy. *Represents summary outcomes across public and private sectors. †Active case ﬁ nding in speciﬁ c risk groups was not 
considered because of modelling limitations. 
Table 1: Intervention scenarios for China, India, and South Africa
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Cost estimation 
Models produced standardised outputs describing service 
use under each scenario, and outputs to estimate the 
economic burden of tuberculosis on patients and 
households. We also did a systematic review20 to collate and 
synthesise unit costs for each country. Empirical 
tuberculosis cost data are limited;20 where local values were 
unavailable we adapted estimates from other settings 
using local prices, holding country consultations to ensure 
face validity. We developed country-speciﬁ c cost models to 
combine service use estimates with unit costs. We divided 
cost categories into diagnosis (ie, active or passive 
screening, tuberculosis diagnosis, and drug resistance 
testing), ﬁ rst-line treatment for active disease, multidrug-
resistant (MDR) tuberculosis treatment, treatment of 
latent infection for HIV-positive individuals (ie, isoniazid 
preventive therapy; South Africa only), and programme 
overheads (ie, high-level overheads supporting service 
delivery). We estimated direct intervention costs and 
changes in the costs of core services (eg, passive detection 
and treatment) indirectly aﬀ ected by policy change. To 
estimate programme overheads, we examined past 
programme expenditures and consulted with WHO and 
country experts. Patient-incurred costs were calculated as 
the sum of direct medical costs (ie, fees paid to providers to 
receive care [eg, consultation fees] and to purchase drugs), 
direct non-medical costs (ie, expenses incurred to receive 
care, such as travel costs, excluding fees paid to providers), 
and indirect productivity costs (ie, income loss due to 
tuberculosis symptoms or treatment, and opportunity cost 
of productive activity forgone due to untreated active 
disease or time taken to receive treatment). Several 
intervention strategies used re imbursements or incentives 
paid for attending care to oﬀ set patient-incurred costs. 
Additional details on the costing approach and input 
values are shown in the appendix pp 17–31. 
We report economic costs from several perspectives: 
a tuberculosis service perspective, representing costs 
borne by national tuberculosis programmes and 
associated service providers; a health service perspective, 
summing tuberculosis service costs (for South Africa, 
costs or cost savings associated with ART were also taken 
into account); and a patient perspective, including costs 
or cost savings realised by individuals with active 
tuberculosis or receiving tuberculosis care; as well as a 
societal perspective combining patient and health service 
costs. We did sensitivity analyses for unit costs and 
programme overheads.
Summary health outcomes
We measured health beneﬁ ts using DALYs. Models 
produced standardised outputs for calculating DALYs 
averted compared with the base case. Outputs included 
deaths by age and year, and the yearly population 
distribution across tuberculosis-related and HIV-related 
health states (appendix pp 8–10). Disability weights 
(appendix p 11) were derived from a multicountry 
valuation study,21 and remaining life expectancy 
(appendix p 12) from country-speciﬁ c life tables22 (values 
not truncated at the analytic horizon). 
Scenario comparisons 
In all scenarios, the assumptions were that interventions 
would reach peak coverage before 2025 and that they 
would be extended to 2035 maintaining 2025 coverage 
levels. This 20 year evaluation period balanced conﬂ icting 
concerns: that longer-term projections would be 
increasingly unreliable, but that a short evaluation period 
Institutions Model 
type
Model 
calibration 
Age structure Population strata Countries
AuTuMN Australian Institute of Tropical Health 
& Medicine, University of Melbourne, 
Monash University, Burnet Institute
D Algorithmic <15 and 15+ years MDR/non-MDR tuberculosis, tuberculosis care access. For South Africa: 
HIV/ART/CD4 status
China, India, 
South Africa
Harvard Harvard University, Yale University D Bayesian 15+ years HIV/ART/CD4 status, multiple tuberculosis strains, tuberculosis 
treatment history, tuberculosis care access
China, India, 
South Africa
Hopkins Johns Hopkins University D Manual 15+ years HIV/ART/CD4 status, MDR/non-MDR tuberculosis South Africa
ICPHFI Public Health Foundation of India, 
Imperial College London
D Algorithmic 15+ years MDR/non-MDR tuberculosis, tuberculosis treatment history India
IDM Institute for Disease Modeling I Bayesian By month of age, 
0–100 years 
MDR/non-MDR tuberculosis, provider and tuberculosis treatment 
history
China
NTU National Taiwan University D Manual 15+ years MDR/non-MDR tuberculosis, health-care system, tuberculosis treatment 
history
China
STAMP Stanford University I Grid Search By month of age, 
0–100 years
MDR/non-MDR tuberculosis, sex, tuberculosis treatment history and 
treatment type, time since infection and progression
India
TIME London School of Hygiene & Tropical 
Medicine
D Manual <15 and 15+ years HIV/ART/CD4 status, MDR/non-MDR tuberculosis, tuberculosis 
treatment history
China, India, 
South Africa
UGA University of Georgia D Manual <15 and 15+ years HIV/ART status, MDR/non-MDR tuberculosis South Africa
D=deterministic compartmental model. I=individual-based, stochastic microsimulation. MDR=multidrug-resistant. ART=antiretroviral therapy. CD4=CD4 cell count. 
Table 2: Characteristics of participating models
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would exclude important policy consequences, as health 
beneﬁ ts are lagged relative to implementation costs.
We summed costs and DALYs over the 20 year period 
(2016–35). For cost-eﬀ ectiveness analyses, we discounted 
these outcomes at 3% per year. Costs represent 2014 US$ 
(equal to 6·1 Chinese Yuan, 60·9 Indian Rupees, and 
10·8 South African Rand). Model results are presented 
individually and averaged across models. Cost-
eﬀ ectiveness ratios were calculated as mean incremental 
cost divided by mean incremental health beneﬁ ts for 
each scenario, as compared with base case. To describe 
aﬀ ordability, we compared annual undiscounted costs 
for each scenario, averaged across models with equal 
weights. As we estimated economic costs, annual results 
are a smoothed version of actual ﬁ nancial needs.
Role of the funding source 
DPC and PD are employees of the Bill & Melinda Gates 
Foundation, which funded the study. These authors were 
acting as subject matter experts rather than agency 
representatives, and did not have veto power over any 
study decision. The corresponding author had full access 
to all data and ﬁ nal responsibility for the decision to 
submit for publication. 
Results 
The models for China and South Africa had fairly 
consistent results in terms of incremental costs (ﬁ gure 1). 
In China, introduction of Xpert MTB/RIF seemed more 
expensive than expansion of access to care and 
improvement of treatment quality, because of high 
diagnostics costs and increased volume for MDR 
tuberculosis treatment. In South Africa, expansion of 
access to care had higher costs than other single-
intervention scenarios, because of the high costs of 
expanding screening in primary care. Results for India 
showed clear diﬀ erences between models. In particular, 
the results for expansion of access to care diﬀ ered, with 
some models predicting cost savings over the 20 year 
period. This diversity of results points to the uncertain 
consequences of private sector intervention—central to 
several scenarios modelled for India—and diﬀ erent 
assumptions about the eﬀ ect of shifting patients from 
low-quality care to high-quality care.
For incremental patient-incurred costs, most inter-
vention scenarios showed cost savings compared with 
the base case (ﬁ gure 2). These cost savings resulted from 
reduced disease burden and from the inclusion of social 
protection or incentives paid for attending care, or both, 
in many intervention scenarios. By contrast, incremental 
patient-incurred costs were positive for the scenario of 
introducing Xpert in China, because of improved 
diagnosis of MDR tuberculosis and high costs that 
patients incur at present to receive second-line treatment. 
For India and South Africa, expansion of access to care 
generated the greatest patient cost savings among the 
single-intervention scenarios.
Figure 3 presents incremental costs, health beneﬁ ts 
(ie, DALYs averted), and cost-eﬀ ectiveness ratios from 
both health service and societal perspectives for each 
intervention scenario compared with the base case (see 
appendix pp 13–15 for results of individual models). 
Results for South Africa included any costs or cost 
savings from changes in ART service volume. Exclusion 
of these costs reduced cost-eﬀ ectiveness ratios by 
10–20% (appendix p 16). In China, Xpert introduction 
averted fewer DALYs at higher cost than expansion of 
access to care and improvement in treatment, the results 
for which largely overlap. This ﬁ nding might be related 
to the relatively minor increase in sensitivity of the Xpert 
algorithm over current practice and the low success rates 
for MDR tuberculosis treatment at present, both of 
which were features of the modelled scenarios. In India, 
expansion of access to care seemed the most attractive 
among the single-intervention strategies. On average, 
the scenario of improving treatment averted more 
DALYs at lower cost than Xpert introduction or active 
case ﬁ nding, although results for this strategy vary 
widely. Active case ﬁ nding in the general population 
generated minimal health beneﬁ ts and comparatively 
high costs per DALY averted. In South Africa, tuber-
culosis services are predominantly publicly provided, 
and thus patient-incurred costs are lower relative to 
health service costs. Consequently, cost-eﬀ ectiveness 
ratios diﬀ ered little between health service and societal 
perspectives. Cost-eﬀ ectiveness ratios were similar 
across scenarios, although the magnitude of eﬀ ects was 
substantially greater for expansion of access to care than 
for other single-intervention scenarios.
Figure 4 presents average annual tuberculosis service 
costs for each scenario, showing the budgetary impli-
cations of aggressive scale-up. In all three countries, the 
combination scenario required substantially increased 
funding. In China and South Africa, resource require-
ments peaked at about three times existing tuberculosis 
service costs. In China and India, cost increases were 
projected to decline over time, whereas for South Africa 
high spending levels were expected to persist, which is 
attributable to high ongoing costs of expanding access 
to care. 
Major sources of uncertainty relating to costs that 
aﬀ ected our results included, for China, additional 
programme investments needed to support scale-up, 
costs of Xpert introduction, and costs of providing 
second-line treatment. For India, the cost of imple-
menting public–private partnerships to expand access 
was the major source of uncertainty, followed by 
uncertainty around programme costs and Xpert 
introduction costs. For South Africa, the costs of 
implementing mobile health services to increase access 
was the major source of uncertainty, followed by the 
costs of implementing symptom screening in primary 
care. Full results of the sensitivity analysis are given in 
appendix pp 31–33.
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Discussion 
The post-2015 End TB Strategy aims to reinvigorate action 
on tuberculosis control and achieve substantial and rapid 
reductions in incidence and mortality. In this study, we 
assessed the costs and cost-eﬀ ectiveness of aggressive 
expansion of tuberculosis services with existing technology 
and interventions. Compared with current practice, all 
intervention scenarios in India and South Africa—and all 
but the scenario of Xpert introduction in China—had a 
cost per DALY averted that fell below the country’s gross 
domestic product (GDP) per person, even before patient 
cost savings were considered. GDP per person is a 
conventional threshold for identifying highly cost-eﬀ ective 
inter ventions,23,24 yet many potential public health 
interventions meet this criterion.25 Recent work has 
highlighted that this threshold might not adequately reﬂ ect 
Figure 1: Incremental tuberculosis service costs for 2016–35 for each intervention scenario, compared with the base case, by country and model
Costs below $0 represent cost savings compared with the base case. Intervention scenarios for each country are described in table 1, and details of each model are provided in table 2 and by Houben 
and colleagues.2 IPT=isoniazid preventive therapy. MDR=multidrug-resistant. *Sum of all cost categories. 
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opportunity costs in many settings.26 However, in view of 
the very low costs per DALY averted for many interventions 
and the substantial reductions in economic burden for 
patients, the results suggest that some form of expansion 
of tuberculosis services is likely to be cost-eﬀ ective for each 
country, and this ﬁ nding is robust because it is supported 
by the results of every participating model.
Involvement of experts from each country was crucial 
for the development of realistic policy scenarios. The 
process of developing these scenarios revealed the 
importance of local epidemiology and care patterns in 
determining the relevant interventions for a particular 
setting, such that important interventions for one 
country (eg, private sector intervention in India and 
isoniazid preventive therapy for HIV-positive individuals 
in South Africa) were thought irrelevant or to have 
minimal beneﬁ t for the other countries. Therefore, the 
activities suggested for each scenario diﬀ ered between 
Figure 2: Incremental patient-incurred costs for 2016–35, for each intervention scenario, compared with the base case, by country and model
Costs below $0 represent cost savings compared with the base case. Intervention scenarios for each country are described in table 1, and details of each model are provided in table 2 and by Houben 
and colleagues.2 IPT=isoniazid preventive therapy.
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countries. Despite this heterogeneity, a consistent 
ﬁ nding across countries was the importance of 
expanding access to care, thereby reducing the duration 
of infectiousness and mortality risks for individuals with 
active infection. The combination scenario produced the 
largest average reduction in DALYs in each country, 
Figure 3: Cost-eﬀ ectiveness ratios of intervention scenarios compared with base case
Costs and DALYs were summed over the period 2016–35, discounted at 3% per year. Values and bold lines connected to the origin represent cost-eﬀ ectiveness ratios calculated from costs and health 
beneﬁ ts averaged across models. Dominant scenarios represent improved health and reduced costs compared with the base case. Dashed lines connect individual model results to the overall average. 
Shaded areas represent the region spanned by the set of model results for each intervention scenario, and reﬂ ect the relative heterogeneity of ﬁ ndings for a particular scenario. Intervention scenarios 
for each country are described in table 1. DALYs=disability-adjusted life-years. IPT=isoniazid preventive therapy.  
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followed by expansion of access to care, although with a 
higher cost per DALY averted than other interventions in 
South Africa. In India and South Africa, expanding 
access to care had a substantially greater eﬀ ect than 
improving treatment, whereas in China this diﬀ erence 
was only marginal, reﬂ ecting China’s past success in 
improving case detection. 
For both India and China, Xpert introduction had a 
smaller health eﬀ ect and higher costs than improving 
treatment or expanding access, despite Xpert 
producing major improvements in the detection of 
MDR tuberculosis. This ﬁ nding is related to low 
treatment quality for MDR tuberculosis in these two 
countries at present, characterised by poor retention 
and cure rates, and by high treatment costs. If the 
major consequence of Xpert introduction is to expand 
access to MDR tuberculosis treatment (as assumed in 
this study), then cost-eﬀ ectiveness ratios are likely to 
Figure 4: Time trends in annual tuberculosis service costs estimated for each scenario, 2016–35
Shaded regions represent annual cost of each cost component averaged across models. Costs were estimated at 2014 price levels and not discounted. Intervention scenarios for each country are 
described in table 1. IPT=isoniazid preventive therapy. MDR=multidrug-resistant. 
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remain high while the treatment costs of MDR 
tuberculosis remain high. 
Despite our broadly positive cost-eﬀ ectiveness ﬁ ndings, 
our results raise concerns regarding aﬀ ordability. In all 
three countries, the annual tuberculosis service costs of 
the combination intervention were more than double the 
base case levels and remained elevated throughout the 
20 year projection (ﬁ gure 4). For India and South Africa, 
the average annual increase in spending required in the 
ﬁ rst 5 years of the combination scenario (compared with 
the base case) represented 3–4% of present government 
health sector funding, compared with only 0·15% in 
China. Only in India was the eﬀ ect on tuberculosis 
burden suﬃ  cient to return the budget to the same level 
as the base case after 20 years. Although human resource 
needs and other health system constraints were not 
modelled explicitly, they might also present major 
challenges to scale-up. 
Although aﬀ ordability and health system constraints 
remain a challenge, a key ﬁ nding of this study is that, 
across all three countries, more aggressive tuberculosis 
policy would substantially reduce the economic burden 
of tuberculosis on patients and their families. These 
results reﬂ ect reductions in direct costs and reductions 
in income loss from early identiﬁ cation and eﬀ ective 
treatment and prevention. For India and China, several 
interventions directly targeted the costs borne by patients, 
using such reimbursements and monetary incentives to 
the patient to improve patient adherence to eﬀ ective 
diagnosis and treatment. Factoring the eﬀ ects on patient-
incurred costs into the cost-eﬀ ectiveness ratio will 
substantially strengthen the investment case for 
expanding tuberculosis services, with both expansion of 
access to care and improvement in treatment producing 
net savings in societal costs in the evaluation period.
Despite this study’s strengths and breadth, care should 
be taken in drawing conclusions about the cost-
eﬀ ectiveness of any one intervention approach. Although 
we investigated a range of interventions, because of the 
complexity of using multiple models we considered only a 
restricted set of options. In reality, each intervention could 
be implemented at diﬀ erent scale and in various 
combinations with one another, and other interventions 
might also be considered. By comparing our set of 
intervention scenarios with the base case, we provide an 
initial scoping of the eﬀ ects that might be achieved with 
each approach and highlight broad priority areas. However, 
ideally a full set of mutually exclusive strategies would be 
compared simultaneously, to identify the optimal set of 
services for a given budget or cost-eﬀ ectiveness threshold. 
A consequence of our more limited approach is that even 
though the combination scenario seemed cost-eﬀ ective 
compared with current practice, it is possible that another 
combination—potentially involving a subset of 
interventions or components of the intervention scenarios, 
more or less aggressive scale-up, or interventions not be 
considered in this analysis—might be optimal. 
To our knowledge, we are the ﬁ rst to use multiple 
independently developed models to assess the cost-
eﬀ ectiveness and aﬀ ordability of tuberculosis inter vention 
options. An important beneﬁ t of this approach was the 
opportunity to compare model results and in so doing 
understand the variation in predictions across models. 
Research in HIV has highlighted the variation in results 
possible when modelling complex disease and health 
system dynamics,25,27 and by using multiple models we 
were able to identify major uncertainties that would remain 
undetected by single-model analyses. We found substantial 
variation in the net health and economic consequences 
predicted for several inter vention scenarios, and in the 
rankings of interventions implied by these results. Since 
we applied a standard cost model, this variation is primarily 
due to uncertainty in the processes of tuberculosis 
epidemiology and interventions in high-burden settings—
realised as diﬀ erences in model structure and para-
meterisation—as well as uncertainty about how speciﬁ c 
programme actions will aﬀ ect tuberculosis epidemiology 
and outcomes.28 For costs, we had few empirical data for 
several interventions, and for the programme costs of 
supporting scaled-up service provision and addressing 
health system constraints and increasing use. Our results 
are sensitive to these uncertainties. Because of the 
complexity of using multiple models, we were unable to 
systematically investigate uncertainty in individual epi-
demiological parameters, yet these uncertainties are also 
likely to be consequential. These uncertainties are related 
to the nature of the scenarios we examined, which were 
designed to extend the reach and quality of services far 
above current levels. Although the use of multiple models 
provides some indication of the uncertainty, these 
projections will not include unanticipated (and therefore 
unmodelled) factors that will limit the health eﬀ ect of 
interventions or increase the costs. The major coverage 
expansions described by the intervention scenarios are 
unprecedented for tuberculosis control, and the possibility 
of unanticipated challenges might be higher than those for 
more conventional policy options.
In this study, we examined the cost-eﬀ ectiveness of a 
set of tuberculosis interventions using multiple models, 
bringing together a community of country experts, 
modellers, and economists. In view of the limitations 
described previously, this study is a crucial ﬁ rst step in 
supporting resource allocation to and within tuberculosis 
control programmes. We found that a wide range of 
context-sensitive interventions are likely to be cost-
eﬀ ective and alleviate ﬁ nancial burden, but at substantial 
cost. Further work is needed to inform tuberculosis 
policy. In the future, policy decisions will ideally involve 
country-led planning processes—exempliﬁ ed by South 
Africa’s investment case analysis in 2016—which can 
more fully examine the range of candidate policies and 
attendant implementation challenges, validate modelling 
assumptions, and evaluate budget needs against options 
for increasing funding.
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